Terms: = Prostate cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Staging
3 results:
1. Targeting Aurora kinases for the treatment of prostate cancer.
Lee EC; Frolov A; Li R; Ayala G; Greenberg NM
Cancer Res; 2006 May; 66(10):4996-5002. PubMed ID: 16707419
[TBL] [Abstract] [Full Text] [Related]
2. Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients.
Schmidt H; De Angelis G; Bettendorf O; Eltze E; Semjonow A; Knichwitz G; Brandt B
Int J Biol Markers; 2004; 19(2):93-9. PubMed ID: 15255540
[TBL] [Abstract] [Full Text] [Related]
3. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens.
Bettuzzi S; Davalli P; Astancolle S; Carani C; Madeo B; Tampieri A; Corti A
Cancer Res; 2000 Jan; 60(1):28-34. PubMed ID: 10646846
[TBL] [Abstract] [Full Text] [Related]
